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Introduction
Bone-marrow-derived stem cells, including mesen-
chymal stromal cells (MSCs), modulate a range of 
processes relevant to inflammatory demyelinating 
disease including immunoregulation, inflammation, 
neurotrophin production, apoptosis, angiogenesis, 
endogenous neurogenesis and oligodendrogenesis, as 
well as oligodendrocyte migration and remyelination. 
These properties, combined with their favourable 
safety profile, have facilitated early clinical transla-
tion of MSC-based cell therapies for a range of condi-
tions including chronic neurological diseases such as 
multiple sclerosis (MS).1
Although clinical studies of MSC-based therapy are 
already underway in MS, relatively little information 
is available regarding the bone marrow microenvi-
ronment,2 or phenotype of MSCs and other marrow-
derived stem cell populations in MS.3–7 Indeed, it is 
not clear whether previous immunotherapy or the 
inflammatory environment in MS could compromise 
stem cell function.8 The few studies available have 
generally been small and comparators have included 
those with underlying haematological malignancies,2 
cardiac disease9 and bone disease.4,5 They have not 
always been adequately controlled for age and time 
in vitro.
The aim of this study was to characterise the bone 
marrow microenvironment in MS and determine 
whether the expansion potential of MS MSCs is com-
parable to that of control MSCs. Crucially, our data 
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analysis employed a multiple regression model to 
allow for independent effects of age, passage number, 
and presence or absence of disease on proliferation 
and senescence.
Materials and methods
Bone marrow collection
Control bone marrow samples for isolation of MSCs 
were obtained at the time of elective total hip replace-
ment for the indication of osteoarthritis courtesy of 
the Orthopaedic Department, Southmead Hospital 
(UK Research Ethics Committee (REC) 10/H102/69). 
Individuals with a history of immune disease or 
immunotherapy were excluded. Bone marrow sam-
ples from MS patients were obtained from partici-
pants in the ‘SIAMMS-II’ (NCT01932593; UK REC 
13/SW/0255)10 and ‘ACTiMuS’ trials (NCT01815632; 
UK REC 12/SW/0358).11 Both trials include only par-
ticipants with progressive MS, and the ‘ACTiMuS’ 
trial has an additional requirement for progression to 
have occurred within the 12 months preceding trial 
entry. The MS cohort were younger (n = 28, median 
age = 51 years, mean = 51.9 years; control cohort: 
n = 11, median age = 59 years, mean = 59.7 years; 
Student’s t-test: p = 0.003). For full cohort details, see 
Supplementary Information (Table 1). Age was not 
associated with duration of disease progression 
(Spearman’s r = 0.277, p = 0.153). No participants 
with primary progressive MS (n = 10) had been 
exposed to disease-modifying therapy (DMT). Of the 
18 participants with secondary progressive MS, 8 had 
been exposed to beta-interferon and/or glatiramer and 
one had also been treated with alemtuzumab. For the 
experiments examining MSC phenotype in vitro, only 
two participants with secondary progressive disease 
had received beta-interferon, or beta-interferon and 
glatiramer and none had been exposed to alemtu-
zumab or other DMT.
Bone marrow trephine immunohistochemistry
Trephine sections were cut (haematoxylin and 
eosin = 1 µm, immunohistochemistry = 2 µm and reticu-
locytes = 3 µm), mounted and stained (Supplementary 
Information Table 2) following formalin fixation, 
decalcification and paraffin-embedding. Reporting cri-
teria are presented in the Supplementary Information.
Bone marrow harvest analysis
All bone marrow collections were evaluated for cell 
viability, total mononuclear cell count (MNC) and 
specific viable CD34 count.12
Isolation of bone-marrow-derived MSCs
Control bone marrow from the femoral shaft was col-
lected in RPMI medium (Sigma) with 1000-IU hepa-
rin. Samples from patients with MS were aspirated 
from the posterior iliac crest during bone marrow har-
vest and collected in heparin before being transported 
to the laboratory in EDTA (K2) tubes. Subsequently, 
marrow samples were processed in an identical man-
ner and MSCs were isolated from both control and 
MS-affected marrow using density gradient centrifu-
gation as previously described.5,13
MSC differentiation and immunophenotype
To ensure isolated MSCs conformed to international 
defining criteria,14 cell surface immunophenotype, as 
well as adipogenic, osteogenic and chondrogenic dif-
ferentiation potential of MSCs, was examined.5
Immunocytochemistry
Immunocytochemistry was performed as previously 
described,13 and details of antibodies used are pre-
sented in the Supplementary Information (Table 2).
Population doubling time
Population doubling time (PDT) = (CT × ln2)/(N/N0), 
where CT is the time in culture, N is the final number 
of cells and N0 is the initial number of cells seeded.
Colony-forming unit assay
Colony-forming unit (CFU) assay was performed at 
p1, p3 and p5. Cells were treated with trypsin and 
seeded in 6-well plates at 250, 125, 62, 31 and 15 cells/
well. After 14 days, fixed cells were stained with 0.5% 
crystal violet in methanol (Sigma). Calculation of 
CFU efficiency was performed dividing number of 
colonies by the total number of cells seeded, ×100.
Senescence-associated β-galactosidase staining
At p7, p10 and p12, MSCs were seeded at 
5 × 104 cells/35-mm wells and stained at 24 hours for 
senescence-associated β-galactosidase (SA-β-gal 
staining kit, Cell Signaling Technology). The percent-
age of SA-β-gal-positive cells in five random fields 
was calculated.
DNA extraction
Genomic DNA was extracted from 2 × 106 control and 
MS MSCs at p2 and p6 using the GenElute Mammalian 
Genomic DNA Miniprep Kit (Sigma).
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DNA concentrations were determined using a Qubit® 
Fluorometer and Quant-iT™ DNA assay kit (Invitrogen) 
to ensure equal sample loading.
Telomere length assay
TeloTAGGG telomere length assay (Roche) was used 
according to manufacturer’s instructions. Average 
size distribution of terminal restriction fragments 
(TRF) was calculated using the following formula: 
TRF = Σ(OD)/ Σ(OD/L), where OD is the chemilu-
minescent signal and L is the length of TRF obtained 
comparing the location of TRF on the blot relative to 
a molecular weight standard.
Statistical analysis
Unless otherwise stated, statistical analysis employed 
a multiple regression model (STATA v12; StataCorp) 
which, where appropriate, allowed for correlation 
between replicates performed using cells isolated 
from the same individual (cluster option). Non-
parametric bootstrap analysis was used to estimate 
standard errors (SEs) and confidence intervals (CI) to 
account for possible non-normality of the parameter’s 
distribution. All graphs were generated using 
GraphPad PRISM 5™ (GraphPad Software) which 
was also used for statistical analyses other than multi-
ple regression analyses. Unless otherwise stated, bar 
graphs show mean ± SE of the mean, and regression 
lines are fitted with 95% CIs. For all analyses, values 
of p < 0.05 were considered statistically significant.
Results
Morphology, cellularity and fibrosis of MS bone 
marrow microenvironment
All analysed trephines (n = 23) were adequate in size 
and integrity with at least six interstitial spaces; small 
or disrupted specimens were not considered.
Bone marrow trephines from patients with MS con-
tained the expected range of myeloid and erythroid pre-
cursors, and colonies were well formed with normal 
maturation and megakaryocytic morphology and distri-
bution.15 The myeloid:erythroid ratio (M:E) was normal 
(3–4:1) with only a single patient having a decreased 
ratio (2:1, 4.3%). Bone marrow fibrosis was not detected, 
and the bone structure was generally within the expected 
limits although four (17.4%) patients were noted to have 
more prominent bone remodelling/trabeculae.
Bone marrow cellularity was lower than expected for 
age in almost half the patients with progressive MS 
(n = 11, 47.8%), and of these five patients, 22% had 
severe marrow hypoplasia (⩽30% cellularity) not in 
keeping with age (Table 1, Figure 1(b)).
Within the MS cohort, Ki67 expression varied over a 
wide range (20%–90%, Table 1; Figure 1(c) and (d)) 
although the majority of samples showed decreased 
proliferation as assessed by values ⩽60% (n = 14, 
60.9%). As expected, erythroid cells demonstrated 
higher levels of proliferation (75%–90%) than mye-
loid cells (15%–80%). However, 11 MS specimens 
(47.8%) showed markedly reduced proliferation 
within the erythroid compartment (<70%) in the con-
text of globally low levels of proliferation. Although 
the MS specimens had few proliferating megakaryo-
cytes, the proportion was within the expected range 
(10%–25%).
Immunological profile of MS bone marrow
Trephines from MS patients had normal expression of 
CD34+ haematopoietic cells, CD61+ megakaryo-
cytes and CD138+ plasma cells. All specimens were 
negative for P53+ cells and natural killer cells (CD56).
Infiltrates of T- and B-lymphocytes were assessed as 
percentage of overall cellularity using CD3 and CD20 
expression (Figure 2). Infiltrates of T-lymphocytes 
accounted for 5%–20% of cellularity and 
B-lymphocytes accounted for 5%–10% (Table 1). The 
distribution of cells occurred as a dispersed interstitial 
infiltrate and lymphoid nodules (Figure 2).
The majority of MS specimens contained T-cell nod-
ules (n = 13, 56.2%), whereas only three MS samples 
(13%) had B-cell nodules (Figure 2). Two had abnor-
mal distribution of B-lymphoid tissue: one due to 
paratrabecular distribution of B-lymphoid nodule and 
one due to moderate interstitial infiltration. Neither 
patient had B-symptoms, abnormalities on full blood 
count or detectable paraprotein.
The connective tissue compartment incorporating blood 
vessels and stromal cells was analysed. The intermedi-
ate filament vimentin was present in elongated, spindle-
shaped cells distributed as a network within the 
haematopoietic compartment (Figure 3(a) and (b)).
All MS samples demonstrated p16+ staining in cells 
with stromal morphology either as nuclear/perinu-
clear pattern or in a cytoplasmic distribution, and this 
varied with cellularity (Figure 3(c)–(e)). Cells 
expressing nuclear p16 tended to be spindle-shaped 
with a dense staining pattern and located in hypocel-
lular areas, frequently adjacent to adipocytes/fat 
J Redondo, P Sarkar et al.
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(Figure 3(c) and (d)). Those with cytoplasmic p16 
were more rounded with weaker staining and were 
located in more cellular areas (Figure 3(e)).
Bone marrow aspirate
Cell viability was >96% in all cases. Median total 
nuclear count (TNC) was 1 × 108/kg and median 
CD34 cell count was 0.63 × 106/kg (Table 1). As pre-
viously reported, CD34 count adjusted for weight 
declined with increasing age (p = 0.007).16 CD34 
counts in primary progressive disease 
(mean = 0.57 × 106/kg, median = 0.55 × 106/kg) were 
lower than in secondary progressive disease 
(mean = 0.77 × 106/kg, median = 0.69 × 106/kg) but this 
was not significant when adjusted for age (p = 0.085). 
There was no significant association between CD34 
count and duration of progression of MS.
MSC isolation and immunophenotype
Bone-marrow-derived MSCs from both control 
(n = 11) and MS (n = 16) individuals displayed 
characteristics distinctive of MSCs in culture;14 cells 
were plastic-adherent with elongated, fibroblast-like 
morphology. Culture expanded MSCs from MS 
patients could be induced to undergo adipogenic, 
osteogenic and chondrogenic differentiation as previ-
ously described.5
Both control and MS MSCs displayed high expres-
sion of cell surface mesenchymal markers including 
CD90, CD105, CD73, CD271, CD44 and low expres-
sion of CD45 (data not shown). Immunocytochemistry 
confirmed expression of CD105, CD73, CD271, 
fibronectin and beta-III (BIII) tubulin in control and 
MS MSCs (data not shown).
Expansion potential of MSCs declines with age 
and expansion in vitro
As expected, MSC expansion at higher passage (p) 
numbers was slow and associated with morphological 
changes previously reported to be associated with 
senescence including increased cell size and cytoplas-
mic granularity.17 To investigate the proliferation 
Figure 1. Cellularity and cell proliferation in marrow from subjects with MS. (a, b) MS trephine with cellularity and (c, 
d) cell proliferation as determined by Ki67 expression (a, c) considered normal for age (50 years) and (b) hypocellular 
(40% instead of 60%) with (d) reduced proliferation (20%) from a participant aged 39 years. Scale bar: 100 µm.
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capacity of MSCs prior to expected senescence in 
vitro, PDT was calculated sequentially from p1 to p7 
for MSCs isolated from 8 control subjects and 15 
patients with MS. PDT increased with in vitro pas-
sage for both MS and control MSCs (Figure 4(a)) and 
PDT at p5 was significantly longer than PDT at p1 
(comparison of PDT at p1 and p5 using Wilcoxon 
matched-pairs t-test, p < 0.0001).
Data were analysed using a multiple regression model 
with cluster analysis to allow for correlation between 
samples isolated from the same individual and effects 
of age, passage number and, where relevant, duration 
of progression of MS. Independent effects of age 
(p = 0.002), passage number (p < 0.0001) and presence 
of disease (p < 0.0001) were observed. In the MS 
cohort, collinearity was not observed between age and 
duration of MS disease progression and the latter had 
an independent, statistically significant effect on PDT 
(p = 0.012) (Figure 4(b) and (c)).
CFU assays were performed at p1, p3 and p5 using MSC 
cultures from 8 control subjects and 15 patients with MS. 
A decline in CFU was seen sequentially with increasing 
passage number (Figure 4(d)); comparison of CFU at p1 
and p3, p3 and p5, and p1 and p5 was performed using 
Wilcoxon matched-pairs t- test and the difference was 
highly significant for each analysis (p < 0.0001).
Using the multiple regression model with cluster 
analysis, negative independent statistically significant 
effects of age (p < 0.001), presence of MS (p = 0.004) 
and passage number (p < 0.0001) were seen on CFU 
number. Within the MS cohort, there was an inde-
pendent effect of duration of progression (p = 0.008) 
and collinearity with age was not observed (Figure 
4(e) and (f)). There was no difference in CFU number 
in the samples isolated from those with primary or 
secondary progressive disease.
MSC Stro-1 expression decreases with time in 
culture and duration of progressive MS
The expression of the early mesenchymal precursor 
marker Stro-1 was analysed in control and MS MSCs 
by immunocytochemistry at p1 and p5 (Figure 5; 
Figure 2. B- and T-cell infiltrates and nodules in bone marrow trephines from patients with MS. (a, b) Both CD3-
positive and (c, d) CD20-positive infiltrates were noted. The majority of MS trephines had (b) T-cell nodules but few 
samples had CD20-positive nodules. Scale bar: 100 µm.
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control: n = 6; MS: n = 10). Stro-1 expression was 
observed uniformly in a sub-population of small, 
round cells with small nuclei, some of which were 
noted to be mitotically active (Figure 5(a)–(c)). As 
expected, the proportion of Stro-1-positive cells 
declined between p1 and p5 (Figure 5(f); Wilcoxon 
matched pairs t-test, p = 0.0001).18 Multiple regres-
sion modelling with cluster analysis demonstrated 
independent negative effects of age (p < 0.0001), pres-
ence of MS (p = 0.001) and passage number 
(p < 0.0001) on Stro-1 expression. The proportion of 
Stro-1+ cells declined with increasing duration of MS 
disease progression (Figure 5(g) and (h); p < 0.0001). 
Collinearity of duration of progression with age was 
not observed and there was no difference in Stro-1 
expression between samples isolated from patients 
with primary or secondary progressive disease.
MS MSCs display accelerated senescence in vitro
At passages p7, p10 and p12 β-galactosidase staining 
was performed to visualise senescent cells (control: 
n = 8; MS: n = 15). As expected, the percentage of 
blue, senescent cells increased with in vitro passage 
number for MSCs from both control and individuals 
with MS (Wilcoxon matched-pairs t-test, p < 0.0001). 
Independent effects of age (p = 0.024), presence of 
MS (p = 0.02) and passage (p < 0.0001) were observed. 
The effect attributable to disease duration did not 
reach statistical significance (p = 0.063), and there 
was no difference in β-galactosidase expression 
between samples isolated from patients with primary 
or secondary progressive disease.
MS MSCs have accelerated telomere shortening 
with expansion in vitro
DNA was isolated from control MSCs (n = 6) and MS 
MSCs (n = 10) at passage 2 and 6 to facilitate meas-
urement of telomere length. The number of days in 
culture was constant between samples isolated for MS 
(p2 mean = 30 days; p6 mean = 105.3 days) and control 
MSCs (p2 mean = 30.6 days; p6 mean = 106.2 days) 
(Mann Whitney’s test: p2, p = 0.79; p6, p = 0.87).
Figure 3. Vimentin and p16 expression in cells with stromal morphology. (a, b) Vimentin-positive cells with elongated, 
spindle-shaped morphology were noted to form a network within the marrow. (c, d) Cells expressing p16 in a 
predominantly nuclear distribution also had spindle-shaped morphology and were distributed within hypocellular areas, 
(e) while those with a more cytoplasmic pattern of staining were located in more cellular areas of marrow.
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As expected, there was a negative association between 
TRF length and age at both p2 (Pearson’s r = −0.537; 
p = 0.032) and p6 (Pearson’s r = −0.722; p = 0.002). 
There was no significant difference in TRF between 
samples isolated from control subjects and those with 
MS (Figure 6(a)). TRF length also decreased with 
increasing passage number for both control and MS 
MSCs, but comparison of TRF between p2 and p6 
reached statistical significance only in MS MSCs 
(paired Student’s t-test, p = 0.004) consistent with 
accelerated telomeric loss with ex vivo expansion of 
MSCs from MS patients (Figure 6(b)). Using multiple 
regression, significant effects of age (p = 0.024) and 
passage (p < 0.0001) were observed but there was no 
significant association between TRF length and pres-
ence of MS, duration of disease progression or sub-
type of progressive disease.
Discussion
Treatment of progressive MS represents a major 
unmet clinical need, and there has been early and 
rapid translation of bone-marrow-derived cell therapy 
from in vitro experiments and those employing in 
vivo models of demyelination to clinical studies.1,19 
However, few studies have examined the phenotype 
of MS-patient marrow and MS MSCs in detail.
Carrai et al.2 compared bone marrow from patients 
with non-Hodgkin’s lymphoma and MS and reported 
reduced cellularity in MS with a trend towards 
increased fibrosis and reduced matrix metallopepti-
dase-9 (MMP-9) expression. Others have reported 
similarity in B- and T-cell populations in marrow 
aspirates from patients with MS or cardiac disease9 
although relative increases in IgA20 and reduced 
populations of NK cells9 have been noted. 
Significantly, these studies did not always control 
for effects of age and/or comparator groups were 
not always healthy.
Successful isolation of MSCs from patients with MS 
has previously been reported3–7 although, as with 
studies of marrow, control groups have not always 
been age-matched and/or disease-free. Broadly, sim-
ilar patterns of mesenchymal differentiation have 
been reported,4–7 but only De Oliveira et al.7 reported 
increased senescence with alterations in the MS 
MSC secretome (reduced interleukin-10 (IL-10) and 
transforming growth factor-beta (TGF-β)) and 
altered gene transcription. Interestingly, they also 
demonstrated reduced MS MSC-mediated anti-pro-
liferative effects on co-culture with allogeneic 
T-lymphocytes. In this study, the subjects were 
young and well age-matched.
Figure 4. Increased PDT and decreased CFU of MS MSCs. (a) PDT increases with time in vitro for MSCs isolated from 
control subjects and patients with MS, (b, c) but accounting for this and the age of subjects, there is an independent effect 
of the presence of MS to increase PDT and this is positively associated with duration of progressive MS. Data from two 
MS cultures which failed to expand prior to p5 are not included in Figure 4(a) although the data were included in the 
multiple regression model. (d) MSC CFU number declines with time in vitro and, when age is taken into consideration, 
CFU number is decreased at all passages when MSCs are isolated from patients with progressive MS. When the 
confounding effect of age is taken into consideration, this was statistically significant. (e, f) There was also a negative 
association between CFU number and duration of progressive MS.
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We are aware of only one other study examining tel-
omere length in bone marrow-derived cells in MS, 
and this was in circulating leukocytes rather than 
MSCs; shortened TRFs were noted in peripheral 
Figure 5. MSC expression of Stro-1 declines with expansion in vitro and in the presence of MS. MSCs are known to 
express fibronectin (Fibro) in vitro and a proportion of MSCs also express Stro-1. (a) Stro-1 expression was noted in 
small, round cells, (b, c) some of which were mitotically active. (d) The proportion of MSCs expressing Stro-1 was 
greater in MSCs isolated from control subjects (e) than in MS MSCs. Scale bar: 200 µm. (f) Expression of Stro-1 by 
MSCs decreases with time in vitro and, when age is accounted for, a smaller proportion of MS MSCs expressed Stro-1 
compared to the proportion of control MSCs which were Stro-1 positive. There was a negative association between the 
proportion of MS MSCs expressing Stro-1 and duration of progressive MS at (g) p1 and (h) p5.
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blood mononuclear cells isolated from patients with 
primary progressive MS, particularly those with 
severe disabilty.21
The recent acknowledgement of the reparative poten-
tial of MSCs for a wide variety of pathological condi-
tions has renewed interest in the importance of the 
stromal compartment of bone marrow. However, more 
recently still, it has been recognised that age,22,23 time 
in vitro24 and disease states8 can influence stromal cell 
function, although whether these changes contribute to 
reduced reparative potential of MSCs and pathogene-
sis, or occur as phenomena associated with ageing 
and/or consequence of disease is not always clear.
Here, we show that the bone marrow niche is indeed 
altered in MS and MSCs isolated from patients with 
MS have reduced ex vivo expansion potential and 
show markers of premature ageing in vitro. 
Furthermore, allowing for effects of age, expansion 
potential of MS MSCs declines in association with 
duration of progressive MS.
Our results corroborate and extend the findings of 
those which have previously reported decreased cel-
lularity of marrow,2 reduced expansion potential7 and 
shortening of TRF length in bone marrow-derived 
cells isolated from patients with progressive MS. 
Furthermore, they highlight the importance of care-
fully controlling for age and time in vitro in related 
studies. We show for the first time that MS marrow is 
phenotypically abnormal with the striking finding of 
T-cell nodules in particular. Although definitive iden-
tification of MSCs in vivo is challenging, reduced 
numbers of Stro-1-positive cells and expression of 
p16 in a predominantly nuclear distribution within 
spindle-shaped, vimentin-positive cells in hypocel-
lular areas support the hypothesis that stromal sup-
port for haematopoiesis is impaired in MS-patient 
marrow.
This study reports limited data on functionality of 
MSCs isolated from patients with MS including 
only proliferation and clonogenic potential, as 
well as mesenchymal differentiation potential. 
Nonetheless, our findings of reduced expansion 
potential and premature senescence of MS MSCs in 
vitro have clear implication for trial protocols 
employing expansion of MSCs for autologous infu-
sion in MS and other conditions, perhaps most par-
ticularly those where oxidative stress is implicated 
in the pathophysiology.21
The findings of changes consistent with accelerated 
ageing in cells of bone marrow origin in MS are of 
potential significance to the pathophysiology of pro-
gressive MS. Although MS is typically considered a 
disease of young adults, progressive disease driven by 
axonal loss is the major determinant of disability25 
and this is clearly influenced by age; the onset of pro-
gressive disease typically occurs around 45 years, 
irrespective of the MS subtype26 and, with advancing 
age patients are more likely to have progressive 
disease.27,28 The reasons underlying the influence 
of age on disease course remain unclear although 
note has been made of age-associated failure of 
remyelination,29 as well as chronic immune system 
activation, reduction in production of trophic factors 
and exhaustion of compensatory mechanisms within 
the central nervous system (CNS; reviewed by 
Larochelle et al.30). Furthermore, processes known to 
occur in normal ageing including genomic instability, 
Figure 6. Accelerated telomere shortening in MS MSCs. (a, b) MSCs isolated from patients with progressive MS 
demonstrate accelerated telomere shortening in vitro. Several samples had identical telomere lengths (**p < 0.01).
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mitochondrial dysfunction, telomere attrition, protein 
misfolding, deregulated nutrient sensing and cellular 
senescence31 have also been implicated in MS patho-
genesis, and the possibility that progressive MS may 
be driven by neurodegenerative, age-related mecha-
nisms has previously been raised.28,32 Although 
chronic inflammation could contribute to premature 
ageing, patients with MS who have been exposed to 
the most potent immunosuppressive treatments are 
not protected from progressive disease, suggesting 
that there are additional contributory factors.33
A potential limitation of our study is the difference in 
MSC origin between control subjects (proximal 
femur) and patients with MS (posterior iliac crest). 
However, pelvic marrow is generally accepted as the 
gold standard for isolation of MNCs and MSCs,34–36 
so reduction in MSC expansion potential seen in 
patients with progressive MS in our study is likely to 
underestimate the magnitude of changes between 
control and MS MSCs. A possible confounding effect 
of the presence of osteoarthritis in the control cohort 
is also acknowledged although, beyond age-related 
effects, a consistent effect of osteoarthritis on isola-
tion and proliferation of MSCs from femoral shaft 
marrow has not been reported.37–40
Although some patients with secondary progressive 
MS had previously been exposed to immunomodula-
tory disease-modifying agents, only two samples with 
a history of exposure to DMTs were included in the 
analysis of MSC phenotype in vitro. None of the 
patients with primary progressive disease had received 
DMTs, and there was no differential effect of disease 
subtype on any of the parameters examined. This 
would suggest that the observed, disease-specific 
effects are unlikely to be attributable to effects of 
prior exposure to DMTs.
Additional investigation will be required to explore 
further the mechanisms underlying the observed 
impairments in MS MSC in vitro expansion potential 
and determine whether MS MSCs have trophic, neu-
roglial protective and immunoregulatory functions 
equivalent to those of MSCs isolated from control 
subjects. It is anticipated that these functions may be 
impaired in MS MSCs and will require correction if 
cell-based therapies for the treatment of MS are to be 
optimised. While use of allogenic MSCs may be an 
option, clarification of the mechanisms underlying 
our findings will contribute to the understanding of 
the pathophysiology of progressive MS and may 
facilitate identification of novel therapeutic interven-
tions, not limited to those employing cell-based 
approaches. These findings are also likely to be of 
relevance to the treatment of other neurodegenerative 
and autoimmune diseases, perhaps most particularly 
those where chronic inflammation and oxidative 
stress play key pathological roles.
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